Henrik Daub received his PhD from the Max Planck Institute for Biochemistry in Martinsried near Munich, for the discovery of fundamental signal transduction mechanisms in cell proliferation. After his postdoctoral studies in RhoGTPase signaling Henrik joined a Munich-based biotech company where he and his team pioneered the development of chemical proteomics methods. Subsequently, as a group leader at the Max Planck Institute of Biochemistry, his research focus shifted towards quantitative phosphoproteomics and chemical biology applications. Henrik received his venia legendi for biochemistry from the Technical University of Munich and is an adjunct professor in the Department of Chemistry. He was a founder of Kinaxo, a Max Planck spin-off company specializing on high-end proteomics services. Henrik joined Kinaxo as Chief Technology Officer in 2010, which was acquired by Evotec in the following year. He now serves as Senior Vice President Science & Technology at Evotec Munich, overseeing the development and application of proteomics technologies for drug and biomarker research. Moreover, Henrik is currently doing a part-time sabbatical in the Department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry.